GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
R

RemeGen Co 688331.SS · CNY

Health Care · Shanghai · 🇨🇳 China

Compare

98.02

+2.96%

Close of 9 Nov 2026, in CNY

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in CNY, from our data supplier.

FY2025

Revenue

CN¥3.25bn

FY2018FY2025

Net income

CN¥708.5m

FY2018FY2025

Free cash flow

−CN¥143.8m

FY2018FY2025

Shareholders' equity

CN¥2.32bn

FY2018FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
RevenueCN¥3.25bnCN¥1.72bnCN¥1.08bnCN¥772.1mCN¥1.42bn−CN¥485,700CN¥2.7mCN¥11.3m
Research and developmentCN¥1.22bnCN¥1.56bnCN¥1.60bnCN¥982.1mCN¥711.0mCN¥465.8mCN¥352.1mCN¥216.4m
Operating incomeCN¥721.4m−CN¥1.46bn−CN¥1.50bn−CN¥995.2mCN¥162.8m−CN¥707.7m−CN¥421.1m−CN¥243.2m
Net incomeCN¥708.5m−CN¥1.47bn−CN¥1.51bn−CN¥998.8mCN¥276.3m−CN¥697.8m−CN¥430.3m−CN¥269.9m
Diluted earnings per share1.29-2.74-2.80-1.780.57-1.42-0.90-0.49

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Total assetsCN¥7.25bnCN¥5.50bnCN¥5.53bnCN¥6.02bnCN¥4.16bnCN¥4.12bnCN¥689.3mCN¥531.1m
Cash and short-term investmentsCN¥2.42bnCN¥759.5mCN¥709.1mCN¥2.07bnCN¥1.76bnCN¥2.77bnCN¥37.5mCN¥6.0m
Total liabilities−CN¥2.32bnCN¥3.51bnCN¥2.09bnCN¥1.04bnCN¥712.8mCN¥523.1mCN¥921.3mCN¥1.03bn
DebtCN¥1.47bnCN¥2.67bnCN¥1.26bnCN¥165.0mCN¥102.8mCN¥197.7mCN¥653.4mCN¥862.8m
Shareholders' equityCN¥2.32bnCN¥1.99bnCN¥3.44bnCN¥4.98bnCN¥3.45bnCN¥3.59bn−CN¥232.0m−CN¥498.2m
Shares outstanding547m536m540m561m485m490m478m547m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Cash from operationsCN¥56.2m−CN¥1.18bn−CN¥1.50bn−CN¥1.26bnCN¥263.6m−CN¥660.1m−CN¥282.7m−CN¥128.0m
Capital spending−CN¥200.0m−CN¥264.6m−CN¥852.8m−CN¥757.5m−CN¥617.3m−CN¥480.8m−CN¥65.2m−CN¥83.7m
Free cash flow−CN¥143.8m−CN¥1.44bn−CN¥2.35bn−CN¥2.02bn−CN¥353.7m−CN¥1.14bn−CN¥348.0m−CN¥211.8m
Dividends paid—−CN¥69.8m−CN¥15.4m—————

Latest quarters

By quarter end

Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024Jun 2024Mar 2024
RevenueCN¥1.53bnCN¥621.9mCN¥572.0mCN¥526.0mCN¥508.0mCN¥467.1mCN¥411.3mCN¥330.4m
Operating incomeCN¥1.26bn−CN¥96.1m−CN¥191.4m−CN¥249.7m−CN¥399.8m−CN¥284.3m−CN¥426.6m−CN¥344.9m
Net incomeCN¥1.26bn−CN¥101.1m−CN¥195.4m−CN¥254.1m−CN¥396.9m−CN¥291.0m−CN¥431.5m−CN¥348.9m
Diluted earnings per share2.30-0.18-0.36-0.46-0.74-0.54-0.80-0.65
Cash from operations−CN¥162.0mCN¥463.0m−CN¥57.0m−CN¥188.0m−CN¥277.0m−CN¥14.0m−CN¥393.0m−CN¥426.0m
Capital spending−CN¥24.0m−CN¥54.0m−CN¥84.0m−CN¥35.0m−CN¥85.0m−CN¥38.0m−CN¥52.0m−CN¥89.0m
Free cash flow−CN¥186.0mCN¥409.0m−CN¥141.0m−CN¥223.0m−CN¥362.0m−CN¥52.0m−CN¥445.0m−CN¥515.0m
Total assetsCN¥7.25bnCN¥5.98bnCN¥5.85bnCN¥5.31bnCN¥5.50bnCN¥5.71bnCN¥5.75bnCN¥5.48bn
Cash and short-term investmentsCN¥2.42bnCN¥1.18bnCN¥1.28bnCN¥721.7mCN¥762.5mCN¥925.1mCN¥876.4mCN¥622.8m
DebtCN¥2.18bnCN¥1.46bnCN¥2.65bnCN¥1.63bnCN¥2.69bnCN¥1.14bnCN¥2.34bnCN¥633.3m
Shareholders' equityCN¥2.32bnCN¥2.32bnCN¥2.36bnCN¥1.77bnCN¥1.99bnCN¥2.37bnCN¥2.66bnCN¥3.08bn

Financial ratios

Data as of 17 Sept 2026

FY2025FY2024FY2023FY2022FY2021FY2020
Operating margin22.2%-81.9%-138.7%-128.9%11.4%145701.3%
Net margin21.8%-85.5%-139.5%-129.4%19.4%143673.3%
Return on equity30.5%-73.9%-44.0%-20.1%8.0%-19.4%
Return on assets9.8%-26.7%-27.3%-16.6%6.6%-16.9%
Free cash flow yield0.4%-1.5%-1.1%-0.8%1.6%-0.3%
Revenue growth89.4%58.5%40.3%-45.8%-293264.9%-118.1%
Earnings growth-148.3%-2.8%51.3%-461.6%-139.6%62.2%
Current ratio1.43x1.05x1.96x3.60x3.73x6.90x
Debt to equity0.94x1.32x0.34x0.01x0.02x0.04x
Equity ratio32.0%36.1%62.2%82.7%82.9%87.3%
Interest coverage10.28x-19.43x-65.03x-147.29x30.59x-24.21x
R&D as a share of sales37.5%90.6%147.4%127.2%49.9%-95907.1%
Buybacks as a share of market value-2.1%0.7%3.7%-15.6%0.9%-2.4%

Growth per year

Compound annual rate

3 years5 years10 years
Revenue61.5%——

Average margins

Over each period

1 year3 years5 years10 years
Operating margin-14.8%-47.4%-45.8%—
Net margin-15.3%-47.9%-44.8%—

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022
Price to earnings60.1-11.0-22.2-43.5
Price to sales13.19.431.056.3

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.